(0.07%) 5 184.18 points
(0.03%) 38 865 points
(-0.14%) 16 326 points
(0.03%) $78.50
(0.32%) $2.20
(-0.39%) $2 322.10
(-0.47%) $27.48
(2.32%) $987.30
(0.22%) $0.930
(0.89%) $10.92
(0.48%) $0.800
(-0.08%) $91.27
Live Chart Being Loaded With Signals
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases...
Stats | |
---|---|
今日成交量 | 580 500 |
平均成交量 | 236 273 |
市值 | 9.03B |
EPS | HKD0 ( 2024-03-20 ) |
下一个收益日期 | ( HKD0 ) 2024-05-20 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 15.93 |
ATR14 | HKD0.0490 (0.28%) |
音量 相关性
Shanghai Henlius Biotech 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Shanghai Henlius Biotech 相关性 - 货币/商品
Shanghai Henlius Biotech 财务报表
Annual | 2023 |
营收: | HKD5.39B |
毛利润: | HKD3.92B (72.64 %) |
EPS: | HKD1.010 |
FY | 2023 |
营收: | HKD5.39B |
毛利润: | HKD3.92B (72.64 %) |
EPS: | HKD1.010 |
FY | 2022 |
营收: | HKD3.21B |
毛利润: | HKD2.37B (73.73 %) |
EPS: | HKD-1.280 |
FY | 2021 |
营收: | HKD1.68B |
毛利润: | HKD1.16B (68.93 %) |
EPS: | HKD-1.858 |
Financial Reports:
No articles found.
Shanghai Henlius Biotech
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。